Publication: Beyond p16 immunostaining: an overview of biomarkers in anal squamous intraepithelial lesions
Authors
Albuquerque, Andreia ; Rios, Elisabete ; Medeiros, Rui
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia. Departamento de Biología Celular e Histología
publication.page.editor
publication.page.department
DOI
DOI: 10.14670/HH-18-053
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Histological grading of squamous
intraepithelial lesions or intraepithelial neoplasia is
fundamental for clinical management and for assessment
of the risk of progression. Biomarkers are important for
assisting correct grading of these lesions, reducing inter
and intraobserver variability and most promising, for
prognosis. Although p16 is the most studied biomarker
in this setting, there are several other biomarkers that
have been studied, reflecting also the need to find a
better single or association option that can be more
suitable, especially for classification purposes. A
PubMed and Embase search was conducted from their
inception until April 2018, aiming to identify biomarkers
evaluated in histological samples of anal squamous
intraepithelial lesions, other than p16. Information on
“Ki-67”, “ProEx™ C”, “p53”, “human papillomavirus
L1 capsid protein”, “stathmin-1”, “minichromosome
maintenance protein”, “p21”, “proliferating cell nuclear
antigen”, “histones”, “human papillomavirus E4”,
“chromosomal abnormalities” and “methylation” was
collected and reviewed. From these, the most studied
biomarker was by far Ki-67. In many cases there were
few studies performed for each biomarker, with no clear
standardized interpretation of the immunostaining. An
increased positive rate with more severe grades of
lesions was shown in many cases. Prognostic data are
limited and need to be further validated.
publication.page.subject
Citation
Histology and Histopathology, Vol.34, nº3, (2019)
item.page.embargo
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/